CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 10 clinical trials at NIH that match your search criteria

Cancer by type/disease: Leukemia (Childhood)

Trial and Protocol Number Graft-Versus-Host Disease	Principal Investigator	Referral Contact
Phase II
A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host Disease NCI-12-C-0068, NCT01557517	Steven Z. Pavletic 301-402-4899	Kristen Cole 301-451-6569 colekr@mail.nih.gov
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD) NCI-04-C-0281, NCT00092235	Steven Z. Pavletic 301-402-4899	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov

Trial and Protocol Number Hematologic/Blood Cancers	Principal Investigator	Referral Contact
Phase II
Multi-institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-pubertal Children and Adults With Molecular Imaging Evaluation NCI-11-C-0136, NCT01338987	Kirsten M. Williams 301-435-6456	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
Phase I/II
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies NCI-08-C-0051, NCT00923910	Alan S. Wayne 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
Phase I
Study of the Biology and Natural History of Disease Outcomes in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies NCI-11-C-0125, NCT01326728	Nancy M. Hardy 301-451-1406	Zetta Blacklock 301-594-2056 bblacklock@mail.nih.gov
A Phase I, Multi-Center, Dose Escalation Study of CAT-8015 in Pediatric Patients With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL) NCI-08-C-0123, NCT00659425	Alan S. Wayne 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
No Phase
Hematologic Malignancy Biology Study NCI-04-C-0102, NCT00923442	Alan S. Wayne 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
Phase I
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies NCI-12-C-0112, NCT01593696	Alan S. Wayne 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias NCI-11-C-0073, NCT01287104	Kristin Baird 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)
Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo^® (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer NCI-10-C-0220, NCT01222780	Alan S. Wayne 301-496-4256	Pediatric Oncology 301-496-4256 1-877-624-4878 (Toll free)

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.